Roche Reports Positive Results From IMmotion151 Kidney Cancer Trial
December 11 2017 - 1:59AM
Dow Jones News
By Nathan Allen
Switzerland's Roche Holding AG (ROG.EB) said Monday that a
phase-3 trial of its Tecentriq and Avastin treatments showed
positive results in patients with a type of advanced kidney
cancer.
Roche said the IMmotion 151 trial met its co-primary endpoint,
slowing the progression of kidney cancer and helping patients live
longer.
The study also showed the combination of Tecentriq and Avastin
provided a statistically significant and clinically meaningful
reduction in the risk of disease worsening or death, compared with
patients who received Sunitinib--a conventional treatment--Roche
said.
"No new safety signals were identified with the combination,"
the company added.
Roche said it was continuing to assess secondary endpoints
associated with the study and that it would present the results at
an oncology conference in 2018.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
December 11, 2017 01:44 ET (06:44 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024